Figure 2

NIM811 inhibits tumor growth in vivo (a) 15 μM of NIM811 caused vacuolization in G22VF cells at 24 h, and substantial cell death at 48 h. Scale bar=50 μm. (b) Nude mice (n=30) were injected subcutaneously with 2E⁶ G22VF cells. When the mice developed tumors larger than 100 mm³, they were randomly divided into three groups to receive treatments: vehicle (1% ethanol+9% cremophor EL+ 90% normal saline), NIM811 intraperitoneal (25 mg/kg), NIM811 oral gavage (25 mg/kg). Using 1 cm³ as cut-off, NIM811-treated mice had slower tumor growth rate than the mice in vehicle group. Curves were significant different by the log-rank (Mantel–Cox) test, P=0.0081. (c) Using tumor size of 2.5 cm³ as killing criteria, NIM811-treated mice survived longer than vehicle-treated mice. Curves were significantly different by log-rank (Mantel–Cox) test, P=0.0198